Irritable-Bowel Syndrome News From Medical News Today
Wed, 08 Sep 2010 03:18:20 +0200
Low Bone Mineral Density Common In Children And Teenagers With Inflammatory Bowel Disease
A thesis from the University of Gothenburg (Sweden) is the first in Scandinavia to study the occurrence of low bone mineral density in children and teenagers with inflammatory bowel disease. Half of the patients in the study showed signs of low bone mineral density...
Tue, 24 Aug 2010 01:00:00 PDT
Stress Management, Diet Changes Improve Irritable Bowel Syndrome Symptoms
When persistent cramping, abdominal pain, bloating, gas, diarrhea and constipation are causing distress and frequent bathroom trips, the next stop should be a visit to the doctor. These symptoms, commonly caused by irritable bowel syndrome (IBS), often can be minimized with diet and lifestyle changes...
Mon, 23 Aug 2010 04:00:00 PDT
Proof That Irritable Bowel Syndrome Is Not In Your Head
Irritable bowel syndrome makes life miserable for those affected -- an estimated ten percent or more of the population. And what irritates many of them even more is that they often are labeled as hypochondriacs, since physical causes for irritable bowel syndrome have never been identified...
Sat, 21 Aug 2010 00:00:00 PDT
UCD Scientists Pinpoint Potential Key Regulator In Battle To Target Inflammatory Bowel Disease (IBD)
Research into inflammatory bowel disease (IBD) led by UCD Conway Institute scientists with national and international collaborators has identified a key regulator involved in maintaining the functional integrity of the gut lining...
Thu, 05 Aug 2010 04:00:00 PDT
N30 Pharma Announces FDA Approval To Initiate Phase 1 Clinical Trial For First-in-Class Drug
N30 Pharmaceuticals, LLC announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD)...
Thu, 05 Aug 2010 04:00:00 PDT
Scientists Target Possible Cause Of One Form Of Bowel Disease
A possible cause of irritable bowel syndrome has been traced to a small piece of RNA that blocks a substance protecting the colon membrane, leading to hostile conditions that can produce diarrhea, bloating and chronic abdominal pain. New research shows that this RNA segment sends signals that stop the activity of the gene that produces glutamine, an amino acid...
Wed, 04 Aug 2010 03:00:00 PDT
Study Finds Structural Brain Alterations In Patients With Irritable Bowel Syndrome
A large academic study has demonstrated structural changes in specific brain regions in female patients with irritable bowel syndrome (IBS), a condition that causes pain and discomfort in the abdomen, along with diarrhea, constipation or both. A collaborative effort between UCLA and Canada's McGill University, the study appears in the July issue of the journal Gastroenterology...
Fri, 23 Jul 2010 02:00:00 PDT
A Guide For Vaccinating The IBD Patient; Findings On Impact Of Gluten-Free Diet In Adult Celiac Patients
A guide for vaccinating the Inflammatory Bowel Disease patient, and studies looking at the impact of a gluten-free diet on adults with celiac disease and the relationship between cognitive factors and treatment response in patients with functional bowel disorders, like IBS, are among the highlights of the June issue of The American Journal of Gastroenterology...
Wed, 23 Jun 2010 02:00:00 PDT
Lubiprostone Successfully Completes Phase 3 Efficacy Trial In Japanese Patients Suffering From Chronic Idiopathic Constipation
Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) and Abbott (NYSE:ABT) today announced that a pivotal phase 3 clinical trial of lubiprostone for chronic idiopathic constipation (CIC) in Japanese patients met its primary endpoint with statistical significance and demonstrated a safety profile consistent with previously reported clinical lubiprostone data...
Thu, 10 Jun 2010 00:00:00 PDT
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment Of Non-Constipation Irritable Bowel Syndrome
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company has submitted an efficacy supplement to NDA 21-361 for XIFAXAN® (rifaximin) 550 mg tablets for the proposed indication of treatment of non-constipation irritable bowel syndrome (Non-C IBS) and IBS-related bloating...
Thu, 10 Jun 2010 00:00:00 PDT
|
